Condition Directory

Depression clinical trials

Directory of U.S. ClinicalTrials.gov public records for Depression. Browse Depression recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 7, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 7, 2026, 1:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

2942

Shown on this page

Current sort

How Depression studies are organized in the registry

Most records use the formal term “major depressive disorder” or MDD rather than “depression” alone, and “treatment-resistant depression” (TRD) labels a distinct, sizable subset. The portfolio includes many behavioral, digital, and device interventions, so the intervention and study-type filters do real work here.

Terms that often appear in related listings

major depressive disorder treatment-resistant depression MDD digital intervention

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 37–48 of 2,942 matching trials for Depression.

Live ClinicalTrials.gov results.

Active filters: "major depressive disorder" Clear condition filters

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Depression
Interventions: TNX-102 SL, Placebo sublingual tablet; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 27
States / cities: Phoenix, Arizona • Buena Park, California • Chino, California + 24 more

Conditions: Major Depressive Disorder
Interventions: CYB003; Drug
Lead sponsor: Cybin IRL Limited; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 42
States / cities: Phoenix, Arizona • Glendale, California • La Jolla, California + 32 more

Conditions: Bi-Polar Disorder, Autism Spectrum Disorder (ASD), Major Depression Disorders, Separation Anxiety Disorder, Social Anxiety Disorder, Generalized Anxiety Disorder (GAD)
Interventions: Digital software application for cognitive performance and activity measurement (QbMobile, investigational device); Device
Lead sponsor: Qbtech AB; Industry
Eligibility: 6 Years to 60 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: Esketamine 56 mg, Esketamine 84 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 7
States / cities: Redlands, California • San Diego, California • Marietta, Georgia + 4 more

Conditions: Depressive Disorder, Major
Interventions: Seltorexant, Placebo, Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 84
States / cities: Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 65 more

Conditions: Major Depressive Disorder
Interventions: Lumateperone, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 25
States / cities: Huntsville, Alabama • Pico Rivera, California • Farmington, Connecticut + 21 more

Conditions: Depressive Disorder, Major
Interventions: Esketamine, Midazolam, Oral Placebo, Intranasal Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 10
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 7 more

Conditions: Opioid Use Disorder, Major Depressive Disorder (MDD)
Interventions: Transcranial Magnetic Stimulation (TMS), Sham Transcranial Magnetic Stimulation (TMS); Device
Lead sponsor: University of Kentucky; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Late Life Depression (LLD), Depression - Major Depressive Disorder
Interventions: High-intensity (6 mA) transcranial direct current stimulation (tDCS); Device
Lead sponsor: Andre Russowsky Brunoni; Other
Eligibility: 60 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Treatment Resistant Depression, Treatment Resistant Depression (TRD)
Interventions: Neuronavigated robotic-enabled TMS, NRX-101, Sham TMS, Oral Placebo; Device · Drug
Lead sponsor: NeuroRx, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Sarasota, Florida • West Palm Beach, Florida • Belmont, Massachusetts

Conditions: Bipolar Depression
Interventions: Lumateperone, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 56
States / cities: Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 38 more

Conditions: Depressive Disorder, Depressive Symptoms
Interventions: Ash, Brief Therapist-Delivered Telehealth; Behavioral
Lead sponsor: Slingshot AI; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

About this Depression clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Depression as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Depression.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Depression clinical trials

How Depression studies are organized in the registry

Filter and sort this condition

Live official records

A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)

An Examination of the Performance of QbMobile in Differential Diagnosis Associated With ADHD Symptoms

A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

Helping Kentuckians Overcome Depression and Opioid Addiction With Brain Stimulation

tDCS for Late-Life Depression

A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial

Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

AI Mental Health Tool vs. Psychoeducation Control

About this Depression clinical trials directory page